Unknown

Dataset Information

0

A self-assembling short oligonucleotide duplex suitable for pretargeting.


ABSTRACT: Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears a cognate receptor for the mAb. Here, we introduce a novel pretargetable RNA based system comprised of locked nucleic acids (LNA) and 2'O-Methyloligoribonucleotides (2'OMe-RNA). The duplex shows fast hybridization, high melting temperatures, excellent affinity, and high nuclease stability in plasma. Using a prototype model system with rituximab conjugated to 2'OMe-RNA (oligo), we demonstrate that LNA-based complementary strand (c-oligo) effectively hybridizes with rituximab-oligo, which is slowly circulating in vivo, despite the high clearance rates of c-oligo.

SUBMITTER: Mallikaratchy P 

PROVIDER: S-EPMC3723235 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A self-assembling short oligonucleotide duplex suitable for pretargeting.

Mallikaratchy Prabodhika P   Gardner Jeffery J   Nordstrøm Lars Ulrik R LU   Veomett Nicholas J NJ   McDevitt Michael R MR   Heaney Mark L ML   Scheinberg David A DA  

Nucleic acid therapeutics 20130713 4


Monoclonal antibodies (mAbs) have naturally evolved as suitable, high affinity and specificity targeting molecules. However, the large size of full-length mAbs yields poor pharmacokinetic properties. A solution to this issue is the use of a multistep administration approach, in which the slower clearing mAb is administered first and allowed to reach the target site selectively, followed by administration of a rapidly clearing small molecule carrier of the cytotoxic or imaging ligand, which bears  ...[more]

Similar Datasets

| S-EPMC8629196 | biostudies-literature
| S-EPMC9398551 | biostudies-literature
| S-EPMC1807971 | biostudies-literature
| S-EPMC4667286 | biostudies-literature
| S-EPMC5698727 | biostudies-literature
| S-EPMC6044717 | biostudies-literature
| S-EPMC5064842 | biostudies-literature
| S-EPMC5993787 | biostudies-other
| S-EPMC5844511 | biostudies-literature
2003-10-22 | GSE759 | GEO